J
J. Erickson
Researcher at Eli Lilly and Company
Publications - 33
Citations - 3258
J. Erickson is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Placebo & Ixekizumab. The author has an hindex of 21, co-authored 33 publications receiving 2865 citations.
Papers
More filters
Journal ArticleDOI
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway,Ken Fujioka,Raymond A Plodkowski,Sunder Mudaliar,Maria Guttadauria,J. Erickson,Dennis Dong Hwan Kim,Eduardo Dunayevich +7 more
TL;DR: Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight and was not associated with increased depression or suicidality events compared with placebo.
Journal ArticleDOI
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E.M. Griffiths,Kristian Reich,Mark Lebwohl,Peter C.M. van de Kerkhof,Carle Paul,Alan Menter,Gregory S Cameron,J. Erickson,L. Zhang,Roberta J. Secrest,Susan Ball,Daniel K. Braun,Olawale Osuntokun,Michael P. Heffernan,Brian J. Nickoloff,Kim A. Papp +15 more
TL;DR: Two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis met the primary endpoints.
Journal ArticleDOI
Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
Thomas A. Wadden,John P. Foreyt,Gary D. Foster,James O. Hill,Samuel Klein,Patrick M. O'Neil,Michael G. Perri,F. Xavier Pi-Sunyer,Cheryl L. Rock,J. Erickson,Holly Maier,Dennis Dong Hwan Kim,Eduardo Dunayevich +12 more
TL;DR: The present findings support the efficacy of combined naltrexone/bupropion therapy as an adjunct to intensive BMOD for obesity, and the former had significantly greater improvements in markers of cardiometabolic disease risk.
Journal ArticleDOI
Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder
Eduardo Dunayevich,J. Erickson,Louise Levine,Ronald Landbloom,Darryle D. Schoepp,Gary D. Tollefson +5 more
TL;DR: The findings of this study support the potential efficacy of mGlu2/3 receptor agonist agents in the treatment of GAD and further studies will be needed to further assess the toxicological and clinical profile of LY354740/LY544344.
Journal ArticleDOI
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Frank L. Greenway,Eduardo Dunayevich,Gary D. Tollefson,J. Erickson,Maria Guttadauria,Ken Fujioka,Michael A. Cowley +6 more
TL;DR: NB caused gradual sustained weight loss over 48 wk; NB32 and NB16 demonstrated greater weight loss in the intent-to-treat population due to lower attrition rates; further study is needed to demonstrate long-term efficacy and safety of NB.